読者です 読者をやめる 読者になる 読者になる

ASTRAL study

仕事

ASTRAL studyの話。

The study, released in the New England Journal of Medicine, showed that receiving a once daily drug combination of sofosbuvir-velpatasvir for a 12 week period was effective in both treatment-naïve and previously treated patients with HCV genotype 1, 2, 4, 5, or 6, including those with compensated cirrhosis (where scarring of the liver has occurred but patients have yet to experience symptoms as a result of it).

で、

The regimen was tested in an international, randomized, double-blind placebo-controlled phase three trial conducted at 81 sites in eight different countries. After 12 weeks, 99 per cent of the 624 patients who had been treated with a daily tablet of sofosbuvir-velpatasvir experienced a sustained virologic response -- the medical term for eradication or cure of HCV -- meaning that patients remained free of the virus three months after completing treatment. None of the 116 patients receiving a placebo experienced the same result.

と効果は良好。

genotype 3にも効く薬を早く。

 

HCV New Drug Research : NEJM EDITORIAL: Simple, Effective, but Out of Reach? Public Health Implications of HCV Drugs